Vaccination coverage for children aged 0–24 months
The data presented in the graph show an overall improvement in vaccination coverage in 2025 compared to 2024 for most antigens in the routine immunization schedule. A noticeable increase is observed in the primary doses of DTaP-IPV-Hib (dose 1, 2 and especially dose 3, from 80% to 90%), as well as in the Rota and PCV vaccines and the DTaP-IPV-Hib-R1 booster dose, which rises from 52% to 66%. A significant improvement is also evident for PCV3, from 60% to 82%, reflecting increased efforts to complete the vaccination schedule. An exception is MMR1, where a decline in coverage is observed from 89% to 82%, indicating the need for further analysis and targeted interventions to increase vaccination against measles, mumps, and rubella. Overall, the positive trend in 2025 demonstrates the strengthening of immunization services, greater public awareness, and institutional commitment to increasing protection against vaccine-preventable diseases.